MDACC Study No:2013-0299 ( NCT No: NCT01841723)
Title:A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Ibrutinib for Treatment of Relapsed Hairy Cell Leukemia
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Ibrutinib
Study Status:Open
Study Description:The goal of this clinical research study is to learn if ibrutinib can help to
control HCL and vHCL. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ibrutinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NCI/CTEP
The Ohio State University
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults